The Tumor Immunology (Tl) Program Area brings basic and translational scientists together into an environment that has spawned novel, investigator-initiated immunotherapy clinical trials for melanoma, brain cancers, lymphomas, lung cancer and renal cell carcinoma, among others. The main goals of the Program Area are: 1) to provide an optimal interactive environment to enhance the understanding of tumor immunology, and 2) to develop novel immune-based clinical therapies for patients with cancer. Established intra- and inter-programmatic research areas include: 1) T cell receptor engineering for adoptive cell transfer therapy;2) new platforms for immune monitoring of T cell responses to cancer;3) non-invasive in vivo imaging of tumor antigen-specific T cells;4) immunotherapy for brain cancers;5) the relationship between inflammation and cancer;and 6) the use of antibody fusion proteins, immune-modulating antibodies and chemokines for cancer therapy. The Tl Program Area also houses research efforts both on gene therapy approaches to cancer treatment and on viral oncogenesis, including studies of HIV/AIDS. The Tl Program Area uses nearly all of the JCCC-supported infrastructure and shared resources. The Flow Cytometry Shared Resource is a key facility required for most (if not all) research projects within the Program Area. The Small Animal Imaging Shared Resource has made possible the pursuit of successful projects in T cell imaging, projects that are now being brought from preclinical models to patients. The JCCC/Human Gene Medicine Program Good Manufacturing Practices (GMP) suite has provided the required physical infrastructure for investigators in the Tl Program Area to manufacture cell and gene therapy products in-house, meeting all of the local, state and federal regulatory requirements for human administration. The Tl Program Area is comprised of 37 members, including six

Public Health Relevance

The treatment of cancer by promoting an anti-tumor immune response offers great promise for the future. The Tumor Immunology Program Area brings together basic, translational, and clinical researchers from multiple disciplines to realize this promise. A broad range of therapeutic strategies for enhancing the antitumor immune response are being pursued, with important intra- and inter-programmatic collaborations to test and monitor the success of each strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635434
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$28,121
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Patananan, Alexander N; Sercel, Alexander J; Teitell, Michael A (2018) More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol 3:16-24
Heard, Jeffrey J; Phung, Ivy; Potes, Mark I et al. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69
Kim, Roy Y; Mangu, Darian; Hoffman, Alexandria S et al. (2018) Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain 141:132-147
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Montecino-Rodriguez, Encarnacion; Casero, David; Fice, Michael et al. (2018) Differential Expression of PU.1 and Key T Lineage Transcription Factors Distinguishes Fetal and Adult T Cell Development. J Immunol 200:2046-2056
Black, David S; Cole, Steve W; Christodoulou, Georgia et al. (2018) Genomic mechanisms of fatigue in survivors of colorectal cancer. Cancer 124:2637-2644
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830

Showing the most recent 10 out of 767 publications